Orifarm
Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orifarm's score of 64 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orifarm's reported carbon emissions
In 2024, Orifarm reported total carbon emissions of approximately 3,178,000 kg CO2e for Scope 1 and about 7,300,000 kg CO2e for Scope 2 (market-based). This reflects a slight decrease from 2023, where emissions were approximately 4,420,000 kg CO2e for Scope 1 and about 7,529,000 kg CO2e for Scope 2 (market-based). Orifarm has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and Scope 2 emissions by 30% by 2025 from a 2020 baseline. Additionally, the company has long-term targets to achieve a 54.6% reduction in absolute Scope 1 and Scope 2 emissions by 2033, as well as a 32.5% reduction in Scope 3 emissions within the same timeframe. The company is committed to a net-zero future, with a focus on exponential reductions in emissions towards 2050. Orifarm's targets are aligned with the Science Based Targets initiative (SBTi), ensuring that their reduction strategies are consistent with the global goal of limiting temperature rise to 1.5°C. Overall, Orifarm's proactive approach to managing carbon emissions demonstrates its commitment to sustainability and climate responsibility within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 605,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 395,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
